Literature DB >> 8896408

Blood clotting in minimally altered whole blood.

M D Rand1, J B Lock, C van't Veer, D P Gaffney, K G Mann.   

Abstract

The sequences of events regulating thrombin generation during tissue factor-initiated clotting in whole blood at 37 degrees C in which the contact pathway was suppressed with corn trypsin inhibitor are studied using quantitative Western blotting of factor V, prothrombin, platelet factor 4, antithrombin III, and fibrinogen. In addition, fibrinopeptide A (FPA), thrombin-antithrombin III (TAT) complex formation, and prothrombin fragment 1.2 (F1.2) were measured via commercially available enzyme-linked immunosorbent assays (ELISAs). In a typical experiment initiated with 40 pmol/L recombinant tissue factor, visual clot time (4.5 minutes), was preceded by significant cleavage of factor V resulting in 65% factor Va heavy-chain generation but only 10% light-chain formation. At this point, 50% of the platelet factor 4 is released, suggesting that half (approximately 700 pmol/L) of the platelet prothrombinase sites available have been generated. At clot time, approximately 15 nmol/L thrombin B-chain is present; however, analyses of FPA release demonstrate that only 15% of the thrombin is acting on fibrinogen. This thrombin is produced by the action of 7 pmol/L prothrombinase. The maximum rate of thrombin production is reached well after clot time and is consistent with the presence of approximately 150 pmol/L prothrombinase (at about 7 minutes). These results suggest that factor Xa is the limiting factor for thrombin generation. After 60 minutes, 75% of the initial prothrombin (1.24 mumol/L) is consumed yielding 400 nmol/ L prethrombin 2 and 360 nmol/l thrombin (B-chain) products. The sum of these values (800 nmol/L) is similar to the (corrected) F1.2 concentration determined by ELISA. The incomplete cleavage of prothrombin indicates both the prothrombinase complex and the formation of prothrombinase are inhibited in the reaction. TAT complex measured by ELISA is almost equivalent to B-chain concentration, but sodium dodecyl sulfate stable thrombin-antithrombin III complexes are not observed until well after clot formation and are never equivalent to ELISA-TAT values. At the point of clot formation, 80% of the fibrinogen is depleted from the fluid phase, whereas only 35% to 45% of the FPA is released, suggesting a significant incorporation of uncleaved fibrinogen into the initial clot formed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8896408

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  94 in total

1.  Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.

Authors:  Margaret V Ragni
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

2.  Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.

Authors:  J H Foley; M E Nesheim; G E Rivard; K E Brummel-Ziedins
Journal:  Haemophilia       Date:  2011-09-20       Impact factor: 4.287

Review 3.  Tissue factor controversies.

Authors:  Kenneth G Mann; Jolanta Krudysz-Amblo; Saulius Butenas
Journal:  Thromb Res       Date:  2012-03-07       Impact factor: 3.944

Review 4.  Limitations of conventional anticoagulant therapy and the promises of non-heparin based conformational activators of antithrombin.

Authors:  Qudsia Rashid; Poonam Singh; Mohammad Abid; Mohamad Aman Jairajpuri
Journal:  J Thromb Thrombolysis       Date:  2012-08       Impact factor: 2.300

5.  Taking the thrombin "fork".

Authors:  Kenneth G Mann
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-07       Impact factor: 8.311

6.  Is there value in kinetic modeling of thrombin generation? Yes.

Authors:  K G Mann
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

7.  Oligosaccharides from depolymerized fucosylated glycosaminoglycan: Structures and minimum size for intrinsic factor Xase complex inhibition.

Authors:  Ronghua Yin; Lutan Zhou; Na Gao; Zi Li; Longyan Zhao; Feineng Shang; Mingyi Wu; Jinhua Zhao
Journal:  J Biol Chem       Date:  2018-07-20       Impact factor: 5.157

8.  The role of protease-activated receptor-1 in bone healing.

Authors:  Shu Jun Song; Charles N Pagel; Therese M Campbell; Robert N Pike; Eleanor J Mackie
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

Review 9.  The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery.

Authors:  Saleh Rachidi; Ehab Saad Aldin; Charles Greenberg; Barton Sachs; Michael Streiff; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2013-12       Impact factor: 2.929

Review 10.  Modeling thrombin generation: plasma composition based approach.

Authors:  Kathleen E Brummel-Ziedins; Stephen J Everse; Kenneth G Mann; Thomas Orfeo
Journal:  J Thromb Thrombolysis       Date:  2014-01       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.